Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2021 07:50 ET | Source: Arch Biopartners

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary Cumming School of...
December 29, 2020 08:33 ET | Source: Arch Biopartners

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
December 23, 2020 08:53 ET | Source: Arch Biopartners

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
December 15, 2020 12:52 ET | Source: Arch Biopartners

Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19

Government of Canada contribution up to $6.7 MillionFunding from the department of Innovation, Science and Economic Development through the Strategic Innovation Fund and part of the Government of...
December 10, 2020 07:27 ET | Source: Arch Biopartners

VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Veterans Affairs San Diego Healthcare System...
November 05, 2020 08:04 ET | Source: Arch Biopartners

Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient dosing in Turkey has begun in the Phase...
October 16, 2020 07:00 ET | Source: Arch Biopartners

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial...
October 07, 2020 07:58 ET | Source: Arch Biopartners

Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida

TORONTO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Ministry...
September 10, 2020 08:59 ET | Source: Arch Biopartners

Arch Biopartners Receives Ethics Committee Approval in Turkey for Phase II Trial for LSALT Peptide

TORONTO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the...
September 01, 2020 08:00 ET | Source: Arch Biopartners

Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 patients

TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...